Arvinas (ARVN) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Arvinas

NasdaqGS•Healthcare•Biotechnology

$8.66-0.11(-0.01%)Market open

Market Cap

$538.49M

P/E

57.9x

P/S

1.7x

P/B

1.0x

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

How this company scores

AverageMetricSide Score: 54/100

Strongest: Balance Sheet & Red Flags (21/25); weakest: Cash & Earnings Quality (10/25).

Profitability11/25

Growth12/25

Balance Sheet & Red Flags21/25

Cash & Earnings Quality10/25

Strengths

Rising earningsLow leverageCash-backed earningsProfit converts from growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 57.9x5y range 57.9x – 57.9x

P/S · 1.7x5y range 1.2x – 182.1x

Currently below its 20-quarter median.

P/B · 1.0x5y range 0.8x – 5.4x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $538.49M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $316.70M
Q. Revenue: $249.70M
TTM EBITDA: $-15.20M
TTM Op. Income: $-18.10M
Q. Op. Income: $164.10M
TTM Net Income: $9.30M
Q. Net Income: $169.40M
EPS: $2.61
Shares Out.: $64.80M

$316.70M in TTM revenue declined 15.0% YoY, reaching $249.70M last quarter. TTM EBITDA of $-15.20M and TTM operating income of $-18.10M show growth is flowing through to the bottom line. TTM net income of $9.30M means revenue is converting into profit. Over the past year, TTM revenue is down 15% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 66.0%
Op. Margin: 65.7%
Net Margin: 67.8%

Op. margin of 65.7% is up 384.9% YoY — cost efficiency is improving. Net margin at 67.8% Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 57.9x
P/S Ratio: 1.7x
P/B Ratio: 1.0x

At 57.9x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 1.7x and P/B of 1.0x provide additional context. P/E sits above typical market levels while revenue growth is below 5%.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $675.10M
Cash: $94.30M
Long-Term Debt: $300,000
Book Value: $562.20M
D/E Ratio: 0.0
Debt/EBITDA: 0.0

With $675.10M in assets and $300,000 in long-term debt, D/E is 0.0and book value is $562.20M — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 2 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-48.30M
TTM Free Cash Flow: $-208.80M
FCF Margin: -65.9%
FCF / Net Income: -22.5

TTM FCF of $-208.80M on $-48.30M in operating cash flow. The FCF / Net Income ratio of -22.5x means the business consumes cash — it is not yet self-funding. Across the last 8 quarters, free cash flow has risen for 4 consecutive quarters — an improving trend.